S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
NASDAQ:ALNY

Alnylam Pharmaceuticals - ALNY Stock Forecast, Price & News

$230.74
+12.16 (+5.56%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$216.07
$231.53
50-Day Range
$123.05
$230.74
52-Week Range
$117.58
$231.53
Volume
2.28 million shs
Average Volume
898,794 shs
Market Capitalization
$27.70 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$225.75

Alnylam Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
2.2% Downside
$225.75 Price Target
Short Interest
Bearish
4.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.52
Upright™ Environmental Score
News Sentiment
0.49mentions of Alnylam Pharmaceuticals in the last 14 days
Based on 44 Articles This Week
Insider Trading
Selling Shares
$1.03 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($8.14) to ($4.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

673rd out of 1,293 stocks

Pharmaceutical Preparations Industry

326th out of 619 stocks

ALNY stock logo

About Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals Trading Up 5.4 %

ALNY traded up $11.71 during trading on Monday, hitting $230.29. The company's stock had a trading volume of 47,358 shares, compared to its average volume of 889,481. Alnylam Pharmaceuticals has a twelve month low of $117.58 and a twelve month high of $226.00. The company has a debt-to-equity ratio of 3.85, a current ratio of 3.76 and a quick ratio of 3.62. The stock's fifty day moving average price is $145.22 and its 200-day moving average price is $148.03.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Rating) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.62) by ($0.67). Alnylam Pharmaceuticals had a negative net margin of 110.91% and a negative return on equity of 204.18%. The business had revenue of $224.80 million during the quarter, compared to analyst estimates of $256.06 million. During the same period last year, the firm posted ($1.61) earnings per share. Alnylam Pharmaceuticals's quarterly revenue was up 1.9% compared to the same quarter last year. As a group, sell-side analysts predict that Alnylam Pharmaceuticals will post -8.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on ALNY. Needham & Company LLC lifted their target price on Alnylam Pharmaceuticals from $205.00 to $240.00 and gave the company a "buy" rating in a research report on Thursday. William Blair began coverage on Alnylam Pharmaceuticals in a research report on Tuesday, June 7th. They issued an "outperform" rating on the stock. Cantor Fitzgerald started coverage on Alnylam Pharmaceuticals in a research report on Tuesday, July 12th. They issued a "neutral" rating and a $175.00 target price on the stock. Chardan Capital lifted their price target on Alnylam Pharmaceuticals from $200.00 to $250.00 and gave the company a "buy" rating in a research note on Thursday. Finally, HC Wainwright lifted their price target on Alnylam Pharmaceuticals from $400.00 to $430.00 in a research note on Monday, May 2nd. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $225.75.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,754 shares of the business's stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $150.00, for a total transaction of $263,100.00. Following the completion of the sale, the executive vice president now owns 1,754 shares in the company, valued at $263,100. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 5,349 shares of company stock valued at $1,033,073. 1.40% of the stock is currently owned by company insiders.

Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Stock News Headlines

Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $192.00
Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $240.00
Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $225.00
See More Headlines
Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Company Calendar

Last Earnings
7/28/2022
Today
8/08/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALNY
CUSIP
02043Q10
Employees
1,665
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$225.75
High Stock Price Forecast
$430.00
Low Stock Price Forecast
$98.00
Forecasted Upside/Downside
-2.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
17 Analysts

Profitability

Net Income
$-852,820,000.00
Net Margins
-110.91%
Pretax Margin
-110.67%

Debt

Sales & Book Value

Annual Sales
$844.29 million
Book Value
$4.92 per share

Miscellaneous

Free Float
118,347,000
Market Cap
$27.70 billion
Optionable
Optionable
Beta
0.74

Social Links


Key Executives

  • Mr. Michael W. Bonney B.A. (Age 64)
    Exec. Chairman
    Comp: $317.97k
  • Dr. Yvonne L. Greenstreet M.B.A. (Age 59)
    MBA, MBChB, CEO & Director
    Comp: $1.23M
  • Dr. Akshay K. Vaishnaw M.D. (Age 59)
    Ph.D., Pres
    Comp: $1.09M
  • Mr. Jeffrey V. Poulton M.B.A. (Age 54)
    CFO & Exec. VP
    Comp: $914.05k
  • Mr. Tolga Tanguler M.B.A.
    Exec. VP & Chief Commercial Officer
  • Dr. Alfred W. Boyle Ph.D.
    Chief Technical Operations & Quality Officer
  • Dr. Kevin Joseph Fitzgerald Ph.D. (Age 54)
    Sr. VP, Head of Research & Chief Scientific Officer
  • Ms. Christine Regan Lindenboom
    Sr. VP of Investor Relations & Corp. Communications
  • Ms. Indrani M. Lall Franchini J.D. (Age 50)
    Exec. VP, Chief Legal Officer & Sec.
  • Mr. Mark Baglin
    VP of Global Marketing













ALNY Stock - Frequently Asked Questions

Should I buy or sell Alnylam Pharmaceuticals stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 5 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALNY shares.
View ALNY analyst ratings
or view top-rated stocks.

What is Alnylam Pharmaceuticals' stock price forecast for 2022?

17 Wall Street analysts have issued 12-month target prices for Alnylam Pharmaceuticals' shares. Their ALNY share price forecasts range from $98.00 to $430.00. On average, they predict the company's share price to reach $225.75 in the next year. This suggests that the stock has a possible downside of 2.2%.
View analysts price targets for ALNY
or view top-rated stocks among Wall Street analysts.

How has Alnylam Pharmaceuticals' stock price performed in 2022?

Alnylam Pharmaceuticals' stock was trading at $169.58 at the start of the year. Since then, ALNY stock has increased by 36.1% and is now trading at $230.74.
View the best growth stocks for 2022 here
.

When is Alnylam Pharmaceuticals' next earnings date?

Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our ALNY earnings forecast
.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its quarterly earnings data on Thursday, July, 28th. The biopharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.62) by $0.67. The biopharmaceutical company earned $224.80 million during the quarter, compared to analyst estimates of $256.06 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 204.18% and a negative net margin of 110.91%. The firm's revenue was up 1.9% on a year-over-year basis. During the same period last year, the company posted ($1.61) earnings per share.

What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?

Alnylam Pharmaceuticals updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $870.00 million-$930.00 million, compared to the consensus revenue estimate of $1.09 billion.

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (8.31%), Loomis Sayles & Co. L P (0.69%), TD Asset Management Inc. (0.33%), Candriam S.C.A. (0.29%), Sumitomo Mitsui Trust Holdings Inc. (0.28%) and Tobam (0.15%). Insiders that own company stock include Akshay Vaishnaw, Barry E Greene, Jeffrey W Dunn, John Maraganore, Laurie Keating, Marsha Fanucci, Phillip A Sharp, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends
.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $230.74.

How much money does Alnylam Pharmaceuticals make?

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $27.70 billion and generates $844.29 million in revenue each year. The biopharmaceutical company earns $-852,820,000.00 in net income (profit) each year or ($8.17) on an earnings per share basis.

How many employees does Alnylam Pharmaceuticals have?

Alnylam Pharmaceuticals employs 1,665 workers across the globe.

When was Alnylam Pharmaceuticals founded?

Alnylam Pharmaceuticals was founded in 2002.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The official website for the company is www.alnylam.com. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101.

This page (NASDAQ:ALNY) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.